15353-j-veluchamy

138 | Chapter 5 38. Cany J, van der Waart AB, Tordoir M, Franssen GM, Hangalapura BN, de Vries J, et al. Natural Killer Cells Generated from Cord Blood Hematopoietic Progenitor Cells Efficiently Target Bone Marrow-Residing Human Leukemia Cells in NOD/SCID/IL2Rg^null Mice. PLoS ONE (2013) 8 (6):e64384. doi: 10.1371/journal.pone.0064384. 39. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood (2005) 105 (8):3051-7. doi: 10.1182/blood-2004-07-2974. PubMed PMID: 15632206. 40. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy (2011) 13 (1):98-107. Epub 2010/09/21. doi: 10.3109/14653249.2010.515582. PubMed PMID: 20849361; PubMed Central PMCID: PMCPmc3760671. 41. Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, et al. Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981.PubMed PMID: 28220124 42. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of Cord-Blood Transplantation from Related and Unrelated Donors. New England Journal of Medicine (1997) 337 (6):373-81. doi:10.1056/NEJM199708073370602. PubMed PMID: 9241126. 43. Armeanu S, Krusch M, Baltz KM, Weiss TS, Smirnow I, Steinle A, et al. Direct and natural killer cell- mediated antitumor effects of low-dose bortezomib in hepatocellular carcinoma. Clin Cancer Res (2008) 14 (11):3520-8. Epub 2008/06/04. doi: 10.1158/1078-0432.ccr-07-4744. PubMed PMID: 18519785. 44. Wu L, Adams M, Carter T, Chen R, Muller G, Stirling D, et al. Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells. Clinical Cancer Research (2008) 14 (14):4650-7. doi: 10.1158/1078-0432.ccr- 07-4405. 45. Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. Journal of Hematology & Oncology (2015) 8 :96. doi: 10.1186/s13045-015-0188-3. PubMed PMID: PMC4522136. 46. Dolstra H, Roeven MWH, Spanholtz J, Hangalapura BN, Tordoir M, Maas F, et al. Successful Transfer of Umbilical Cord Blood CD34+ Hematopoietic Stem and Progenitor-derived NK Cells in Older Acute Myeloid Leukemia Patients. Clin Cancer Res. 2017 Aug 1;23(15):4107-4118. doi: 10.1158/1078-0432.CCR-16-2981.PubMed PMID: 28220124 47. Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, et al. Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production. Molecular Cancer Therapeutics (2012) 11 (12):2674- 84. doi: 10.1158/1535-7163.mct-12-0692.